Spero Therapeutics, Inc.·4

Dec 15, 4:07 PM ET

Larkin Cristina 4

4 · Spero Therapeutics, Inc. · Filed Dec 15, 2017

Insider Transaction Report

Form 4
Period: 2017-12-13
Larkin Cristina
Chief Operating Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2017-12-13+62,54062,540 total
    Exercise: $11.63Exp: 2027-12-12Common Stock (62,540 underlying)
Footnotes (1)
  • [F1]The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION